Clinical Effects and Safety of the Use of Methylene Blue for the Treatment of Lumbar Facet Joint Syndrome (2022)

Peer-Reviewed Study · Yu X, Zhang J, Wang M, et al. · January 2022

Yu X et al., 2022-01: Randomized controlled trial of intra-articular methylene blue into lumbar facet joints, finding better pain and function scores than control at 3 and 6 months. The closest human intra-articular joint evidence, but the joint is the lumbar facet, not the knee or hip.

Ultrasound-guided intra-articular MB injection is a safe and effective therapy for patients with LFJS. Intra-articular injection with MB can significantly reduce pain intensity, improve patient lumbar function, pain-related depression and sleep quality, increase total effective rate with no severe adverse side effects.

Yu X et al., 2022-01: Randomized controlled trial of intra-articular methylene blue into lumbar facet joints, finding better pain and function scores than control at 3 and 6 months. The closest human intra-articular joint evidence, but the joint is the lumbar facet, not the knee or hip. Study type: prospective, randomized, controlled trial (not double-blinded). N=120 randomized, 104 followed 6 months (53 MB, 51 control). Country: China (Shanghai East Hospital). Intra-articular MB, ultrasound-guided; concentration/dose not in abstract; 6-month follow-up. Funding/conflicts: not stated. Comparator: control injection (agent not stated in abstract). Single centre, small, unblinded. Study type: randomized trial.